Wuzi Yanzong Pill may reduce movement problems and nerve cell loss by blocking inflammation in a Parkinson’s disease model

Oral administration of Wuzi Yanzong Pill (WYP) in MPTP-induced Parkinson disease mice for 2 weeks ameliorated abnormal motor dysfunction.

• WYP treatment reduced the loss of dopaminergic neurons in the substantia nigra pars compacta.
• The intervention inhibited microglial activation in both MPTP-induced PD mice and LPS-stimulated microglia cells.
• WYP decreased the expression of several inflammatory markers, including IL-6, TNF-α, and IL-1β.
• An increase in IL-10 expression was observed in the substantia nigra of treated PD mice.
• WYP treatment was associated with the inhibition of the NLRP3 inflammasome and the TLR4/MyD88/NF-κB signaling pathway.
• Further investigation is needed to clarify the exact mechanism of WYP's action on these pathways.

Simplified